{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:58:18Z","timestamp":1787497098552,"version":"build-2736575974"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-021-10182-x","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T18:02:20Z","timestamp":1638468140000},"page":"667-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond"],"prefix":"10.1007","volume":"28","author":[{"given":"Angela","family":"Sciacqua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Succurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Armentaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"10182_CR1","doi-asserted-by":"publisher","unstructured":"James SL, Abate D, Abate KH, et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and\u00a0territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"10182_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW (2020) Epidemiology of heart failure. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"10182_CR3","doi-asserted-by":"crossref","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, et al (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail.https:\/\/scite.ai\/reports\/10.1002\/ejhf.483.","DOI":"10.1002\/ejhf.483"},{"key":"10182_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.11.002","author":"L Guariguata","year":"2014","unstructured":"Guariguata L, Whiting DR, Hambleton I et al (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2013.11.002","journal-title":"Diabetes Res Clin Pract"},{"key":"10182_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000691","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D et al (2019) Type 2 diabetes mellitus and heart failure: a scientific statement from the american heart association and the heart failure society of america: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000000691","journal-title":"Circulation"},{"key":"10182_CR6","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0286","author":"JP van Melle","year":"2010","unstructured":"van Melle JP, Bot M, de Jonge P et al (2010) Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. https:\/\/doi.org\/10.2337\/dc10-0286","journal-title":"Diabetes Care"},{"key":"10182_CR7","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0165","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, Blecker S, Pazin-Filho A et al (2010) The association of hemoglobin A1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. https:\/\/doi.org\/10.2337\/db10-0165","journal-title":"Diabetes"},{"key":"10182_CR8","doi-asserted-by":"publisher","unstructured":"Swoboda PP, McDiarmid AK, Erhayiem B et al (2017) Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc.\u00a0https:\/\/doi.org\/10.1161\/JAHA.117.005539","DOI":"10.1161\/JAHA.117.005539"},{"key":"10182_CR9","doi-asserted-by":"publisher","unstructured":"Preiss D, van Veldhuisen DJ, Sattar N et al (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Eur J Heart Fail.\u00a0https:\/\/doi.org\/10.1093\/eurjhf\/hfs067","DOI":"10.1093\/eurjhf\/hfs067"},{"key":"10182_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev061","author":"S Paolillo","year":"2015","unstructured":"Paolillo S, Rengo G, Pellegrino T et al (2015) Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. https:\/\/doi.org\/10.1093\/ehjci\/jev061","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10182_CR11","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0282","author":"JJ Park","year":"2021","unstructured":"Park JJ (2021) Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J. https:\/\/doi.org\/10.4093\/dmj.2020.0282","journal-title":"Diabetes Metab J"},{"key":"10182_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(72)90595-4","author":"S Rubler","year":"1972","unstructured":"Rubler S, Dlugash J, Yuceoglu YZ et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. https:\/\/doi.org\/10.1016\/0002-9149(72)90595-4","journal-title":"Am J Cardiol"},{"key":"10182_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.019","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D (2018) Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.019","journal-title":"J Am Coll Cardiol"},{"key":"10182_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1906","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.1906","journal-title":"JAMA"},{"key":"10182_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.958009","author":"LA Allen","year":"2011","unstructured":"Allen LA, Gheorghiade M, Reid KJ et al (2011) Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.958009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10182_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.679","author":"G Targher","year":"2017","unstructured":"Targher G, Dauriz M, Laroche C et al (2017) In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA heart failure long-term registry. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.679","journal-title":"Eur J Heart Fail"},{"key":"10182_CR17","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0574","author":"M Dauriz","year":"2017","unstructured":"Dauriz M, Targher G, Laroche C et al (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care. https:\/\/doi.org\/10.2337\/dc16-0574","journal-title":"Diabetes Care"},{"key":"10182_CR18","doi-asserted-by":"publisher","unstructured":"MacDonald MR, Petrie MC, Varyani F et al 2008. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehn153","DOI":"10.1093\/eurheartj\/ehn153"},{"key":"10182_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024593","author":"SL Kristensen","year":"2017","unstructured":"Kristensen SL, Mogensen UM, Jhund PS et al (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-PRESERVE trial (irbesartan in heart failure with preserved ejection fraction). Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024593","journal-title":"Circulation"},{"key":"10182_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.020","author":"CA Lawson","year":"2018","unstructured":"Lawson CA, Jones PW, Teece L et al (2018) Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. JACC Heart Fail. https:\/\/doi.org\/10.1016\/j.jchf.2017.08.020","journal-title":"JACC Heart Fail"},{"key":"10182_CR21","doi-asserted-by":"publisher","unstructured":"Triposkiadis F, Xanthopoulos A, Butler J (2019) Cardiovascular aging and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019.\u00a0https:\/\/doi.org\/10.1016\/j.jacc.2019.06.053","DOI":"10.1016\/j.jacc.2019.06.053"},{"key":"10182_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2020.12.001","author":"O Hanon","year":"2021","unstructured":"Hanon O, Belmin J, Benetos A et al (2021) Consensus of experts from the french society of geriatrics and gerontology on the management of heart failure in very old subjects. Arch Cardiovasc Dis. https:\/\/doi.org\/10.1016\/j.acvd.2020.12.001","journal-title":"Arch Cardiovasc Dis"},{"key":"10182_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01035-9","author":"WD Strain","year":"2021","unstructured":"Strain WD, Down S, Brown P et al (2021) Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. https:\/\/doi.org\/10.1007\/s13300-021-01035-9","journal-title":"Diabetes Ther"},{"key":"10182_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0380-x","author":"S Kalra","year":"2018","unstructured":"Kalra S, Sharma SK (2018) Diabetes in the elderly. Diabetes Ther. https:\/\/doi.org\/10.1007\/s13300-018-0380-x","journal-title":"Diabetes Ther"},{"key":"10182_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afx104","author":"SG Parker","year":"2017","unstructured":"Parker SG, McLeod A, McCue P et al (2017) New horizons in comprehensive geriatric assessment. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afx104","journal-title":"Age Ageing"},{"key":"10182_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62167-9","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(12)62167-9","journal-title":"Lancet"},{"key":"10182_CR27","doi-asserted-by":"publisher","unstructured":"Clegg A, Bates C, Young J et al (2016) Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afw039","DOI":"10.1093\/ageing\/afw039"},{"key":"10182_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.10.005","author":"A Pandey","year":"2019","unstructured":"Pandey A, Kitzman D, Reeves G (2019) Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail. https:\/\/doi.org\/10.1016\/j.jchf.2019.10.005","journal-title":"JACC Heart Fail"},{"key":"10182_CR29","doi-asserted-by":"publisher","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) ESC scientific document group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"10182_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0048-7","author":"GJ Biessels","year":"2018","unstructured":"Biessels GJ, Despa F (2018) Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-018-0048-7","journal-title":"Nat Rev Endocrinol"},{"key":"10182_CR31","first-page":"411","volume":"55","author":"K Trachanas","year":"2014","unstructured":"Trachanas K, Sideris S, Aggeli C et al (2014) Diabetic cardiomyopathy: from pathophysiology to treatment. Hell J Cardiol 55:411\u2013421","journal-title":"Hell J Cardiol"},{"key":"10182_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(75)90039-3","author":"SS Ahmed","year":"1975","unstructured":"Ahmed SS, Jafer GA, Narang RM et al (1975) Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J. https:\/\/doi.org\/10.1016\/0002-8703(75)90039-3","journal-title":"Am Heart J"},{"key":"10182_CR33","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2006.3.108","author":"J Wang","year":"2006","unstructured":"Wang J, Song Y, Wang Q et al (2006) Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud. https:\/\/doi.org\/10.1900\/RDS.2006.3.108","journal-title":"Rev Diabet Stud"},{"key":"10182_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.108.813071","author":"M Kurt","year":"2009","unstructured":"Kurt M, Wang J, Torre-Amione G et al (2009) Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging. https:\/\/doi.org\/10.1161\/CIRCIMAGING.108.813071","journal-title":"Circ Cardiovasc Imaging"},{"key":"10182_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-72","author":"RR Lamberts","year":"2014","unstructured":"Lamberts RR, Lingam SJ, Wang HY et al (2014) Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/1475-2840-13-72","journal-title":"Cardiovasc Diabetol"},{"key":"10182_CR36","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.50.627","author":"H Otake","year":"2009","unstructured":"Otake H, Suzuki H, Honda T, Maruyama Y (2009) Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J. https:\/\/doi.org\/10.1536\/ihj.50.627","journal-title":"Int Heart J"},{"key":"10182_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.022","author":"M Cameli","year":"2012","unstructured":"Cameli M, Lisi M, Focardi M et al (2012) Left atrial deformation analysis by speckle tracking echocardiography for prediction of cardiovascular outcomes. Am J Cardiol. https:\/\/doi.org\/10.1016\/j.amjcard.2012.03.022","journal-title":"Am J Cardiol"},{"key":"10182_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.022","author":"JH Liu","year":"2016","unstructured":"Liu JH, Chen Y, Yuen M et al (2016) Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. https:\/\/doi.org\/10.1016\/j.amjcard.2012.03.022","journal-title":"Cardiovasc Diabetol"},{"key":"10182_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2017.01.014","author":"M Tadic","year":"2018","unstructured":"Tadic M, Cuspidi C, Vukomanovic V et al (2018) Layer-specific deformation of the left ventricle in uncomplicated patients with type 2 diabetes and arterial hypertension. Arch Cardiovasc Dis. https:\/\/doi.org\/10.1016\/j.acvd.2017.01.014","journal-title":"Arch Cardiovasc Dis"},{"key":"10182_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.08.027","author":"R Abou","year":"2017","unstructured":"Abou R, Leung M, Khidir MJH et al (2017) Influence of aging on level and layer-specifc left ventricular longitudinal strain in subjects without structural heart disease. Am J Cardiol. https:\/\/doi.org\/10.1016\/j.amjcard.2017.08.027","journal-title":"Am J Cardiol"},{"key":"10182_CR41","doi-asserted-by":"publisher","unstructured":"Sciacqua A, Perticone M, Miceli S et al (2019) Elevated 1-h post-load plasma glucose is associated with right ventricular morphofunctional parameters in hypertensive patients. Endocrine 64.\u00a0https:\/\/doi.org\/10.1007\/s12020-019-01873-5","DOI":"10.1007\/s12020-019-01873-5"},{"key":"10182_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.11.022","author":"YC Lee","year":"2017","unstructured":"Lee YC, Chang CH, Dong YH et al (2017) Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: a nationwide study. Int J Cardiol. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.022","journal-title":"Int J Cardiol"},{"key":"10182_CR43","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S012","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association (2021) Older adults: standards of medical care in diabetes. Diabetes Care. https:\/\/doi.org\/10.2337\/dc21-S012","journal-title":"Diabetes Care"},{"key":"10182_CR44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00198","author":"D LeRoith","year":"2019","unstructured":"LeRoith D, Jan Biessels G, Braithwaite SB et al (2019) Treatment of diabetes in older adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2019-00198","journal-title":"J Clin Endocrinol Metab"},{"key":"10182_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15767","author":"American Geriatrics Society","year":"2019","unstructured":"American Geriatrics Society (2019) Updated AGS beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. https:\/\/doi.org\/10.1111\/jgs.15767","journal-title":"J Am Geriatr Soc"},{"key":"10182_CR46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003795","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1003795","journal-title":"N Engl J Med"},{"key":"10182_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.10.077","author":"HJ Dargie","year":"2007","unstructured":"Dargie HJ, Hildebrandt PR, Riegger GA et al (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with new york heart association functional class I or II heart failure. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2006.10.077","journal-title":"J Am Coll Cardiol"},{"key":"10182_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","author":"DT Eurich","year":"2013","unstructured":"Eurich DT, Weir DL, Majumdar SR et al (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000162","journal-title":"Circ Heart Fail"},{"key":"10182_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0960-8","author":"RE Pratley","year":"2019","unstructured":"Pratley RE, Husain M, Lingvay I et al (2019) Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/s12933-019-0960-8","journal-title":"Cardiovasc Diabetol"},{"key":"10182_CR50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"key":"10182_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1146","author":"F Cosmi","year":"2018","unstructured":"Cosmi F, Shen L, Magnoli M et al (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1146","journal-title":"Eur J Heart Fail"},{"key":"10182_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000691","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D et al (2019) Type 2 diabetes mellitus and heart failure: a scientific statement from the american heart association and the heart failure society of america: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000000691","journal-title":"Circulation"},{"key":"10182_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"10182_CR54","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2868","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Teoh H, Braunwald E et al (2015) Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. https:\/\/doi.org\/10.2337\/dc14-2868","journal-title":"Diabetes Care"},{"key":"10182_CR55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"key":"10182_CR56","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1135","author":"MA Bethel","year":"2017","unstructured":"Bethel MA, Engel SE, Green JB et al (2017) Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care. https:\/\/doi.org\/10.2337\/dc16-1135","journal-title":"Diabetes Care"},{"key":"10182_CR57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889","author":"WB White","year":"2015","unstructured":"White WB, Cannon CP, Heller SR et al (2015) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1305889","journal-title":"N Engl J Med"},{"key":"10182_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62225-X","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(14)62225-X","journal-title":"Lancet"},{"key":"10182_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"10182_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.13995","author":"ME Cooper","year":"2020","unstructured":"Cooper ME, Rosenstock J, Kadowaki T et al (2020) Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and\/or kidney disease: a prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA trial. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/DOM.13995","journal-title":"Diabetes Obes Metab"},{"key":"10182_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.13772","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2019.13772","journal-title":"JAMA"},{"key":"10182_CR62","doi-asserted-by":"publisher","unstructured":"Espeland MA, Pratley RE, Rosenstock J et al (2021) Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial. Diabetes Obes Metab.https:\/\/doi.org\/10.1111\/dom.14254","DOI":"10.1111\/dom.14254"},{"key":"10182_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.13829","author":"G Ledesma","year":"2019","unstructured":"Ledesma G, Umpierrez GE, Morley JE et al (2019) Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: a randomized trial. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/DOM.13829","journal-title":"Diabetes Obes Metab"},{"key":"10182_CR64","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0296","author":"J Shen","year":"2021","unstructured":"Shen J, Greenberg BH (2021) Diabetes management in patients with heart failure. Diabetes Metab J. https:\/\/doi.org\/10.4093\/dmj.2020.0296","journal-title":"Diabetes Metab J"},{"key":"10182_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3024","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. https:\/\/doi.org\/10.1001\/jama.2018.3024","journal-title":"JAMA"},{"key":"10182_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1578590","author":"J Freeman","year":"2019","unstructured":"Freeman J (2019) Management of hypoglycemia in older adults with type 2 diabetes. Postgrad Med. https:\/\/doi.org\/10.1080\/00325481.2019.1578590","journal-title":"Postgrad Med"},{"key":"10182_CR67","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1943","author":"CV Dave","year":"2020","unstructured":"Dave CV, Schneeweiss S, Wexler DJ et al (2020) Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013\u20132018. Diabetes Care. https:\/\/doi.org\/10.2337\/dc19-1943","journal-title":"Diabetes Care"},{"key":"10182_CR68","doi-asserted-by":"publisher","unstructured":"Herrera Comoglio R, Vidal Guitart X (2020) Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): a systematic review and meta-analysis of observational cohort studies. Int J Clin Pract. https:\/\/doi.org\/10.1111\/ijcp.13553","DOI":"10.1111\/ijcp.13553"},{"key":"10182_CR69","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000673","author":"EJ North","year":"2019","unstructured":"North EJ, Newman JD (2019) Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Curr Opin Cardiol. https:\/\/doi.org\/10.1097\/HCO.0000000000000673","journal-title":"Curr Opin Cardiol"},{"key":"10182_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa082","author":"F Marsico","year":"2020","unstructured":"Marsico F, Paolillo S, Gargiulo P et al (2020) Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa082","journal-title":"Eur Heart J"},{"key":"10182_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108737","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2021.108737","journal-title":"Diabetes Res Clin Pract"},{"key":"10182_CR72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"key":"10182_CR73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"10182_CR74","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1607141","DOI":"10.1056\/NEJMoa1607141"},{"key":"10182_CR75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa161291","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa161291","journal-title":"N Engl J Med"},{"key":"10182_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"key":"10182_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"10182_CR78","doi-asserted-by":"crossref","unstructured":"Margulies KB, Hernandez AF, Redfield MM et al (2016) NHLBI heart failure clinical research network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500\u2013508","DOI":"10.1001\/jama.2016.10260"},{"key":"10182_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01049-w","author":"E Longato","year":"2020","unstructured":"Longato E, Di Camillo B, Sparacino G et al (2020) Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/s12933-020-01049-w","journal-title":"Cardiovasc Diabetol"},{"key":"10182_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001451","author":"E Longato","year":"2020","unstructured":"Longato E, Di Camillo B, Sparacino G et al (2020) Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001451","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10182_CR81","doi-asserted-by":"publisher","unstructured":"Longato E, Di Camillo B, Sparacino G et al (2021) Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. Eur J Prev Cardiol.https:\/\/doi.org\/10.1093\/eurjpc\/zwaa081","DOI":"10.1093\/eurjpc\/zwaa081"},{"key":"10182_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa004","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Szummer K et al (2021) Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa004","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10182_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1673","author":"PM Seferovic","year":"2020","unstructured":"Seferovic PM, Coats AJS, Ponikowski P et al (2020) European society of cardiology\/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1673","journal-title":"Eur J Heart Fail"},{"key":"10182_CR84","doi-asserted-by":"crossref","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure. Circulation.\u00a0https:\/\/doi.org\/10.1161","DOI":"10.1161\/CIRCULATIONAHA.117.030012"},{"key":"10182_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13169","author":"J Butler","year":"2020","unstructured":"Butler J, Usman MS, Khan MS et al (2020) Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure. https:\/\/doi.org\/10.1002\/ehf2.13169","journal-title":"ESC Heart Failure"},{"key":"10182_CR86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"10182_CR87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"10182_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034222","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034222","journal-title":"Circulation"},{"key":"10182_CR89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"10182_CR90","doi-asserted-by":"publisher","unstructured":"Cahn A, Mosenzon O, Wiviott SD et al (2020) Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study. Diabetes Care 2020. https:\/\/doi.org\/10.2337\/dc19-1476","DOI":"10.2337\/dc19-1476"},{"key":"10182_CR91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"10182_CR92","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050255","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZI et al (2020) Efficacy of ertugliflozin on heart failure\u2013related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050255","journal-title":"Circulation"},{"key":"10182_CR93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"10182_CR94","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14356","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Karasik A, Melzer-Cohen C et al (2021) Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: analysis from the CVD-REAL 2 study. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.14356","journal-title":"Diabetes Obes Metab"},{"key":"10182_CR95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"10182_CR96","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044133","author":"FA Martinez","year":"2019","unstructured":"Martinez FA, Serenelli M, Nicolau JC et al (2019) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044133","journal-title":"Circulation"},{"key":"10182_CR97","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052503","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052503","journal-title":"Circulation"},{"key":"10182_CR98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10182_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9","journal-title":"Lancet"},{"key":"10182_CR100","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH et al (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"10182_CR101","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. https:\/\/doi.org\/10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"10182_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.056","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R et al (2019) Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056","journal-title":"J Am Coll Cardiol"},{"key":"10182_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4509-7","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartsceer A, Bleijlevens B et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"key":"10182_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1673","author":"PM Seferovi\u0107","year":"2020","unstructured":"Seferovi\u0107 PM, Coats AJS, Ponikowski P et al (2020) European society of cardiology\/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1673","journal-title":"Eur J Heart Fail"},{"key":"10182_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.11.007","author":"G Sesti","year":"2018","unstructured":"Sesti G, Incalzi RA, Bonora E et al (2018) Management of diabetes in older adults. Nutr Metab Cardiovasc Dis. https:\/\/doi.org\/10.1016\/j.numecd.2017.11.007","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10182-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10182-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10182-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T03:07:38Z","timestamp":1682564858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10182-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":105,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["10182"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10182-x","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"14 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}